

## Optimization of GLP1 Fermentation in CGMP Environments

Su-Hyun KWON<sup>1,2</sup>, Jongdae LEE<sup>1</sup>, Chan-Wha KIM<sup>2</sup>

<sup>1</sup>*Process and Business Development Team, Korea Biotechnology Commercialization Center, Korea Institute of Industrial Technology, Incheon, 406-130,* <sup>2</sup>*Dpet. of Biothechnology, Korea University, Seoul, 136-701*

### Abstract

GLP1 (Glucagon-Like Peptides 1) has been considered to have not only insulinotropic but also other antidiabetic effects on patients with Type 2 diabetes [1]. In this study, the GLP1 culture conditions such as initial pH, buffer concentration and temperature were optimized to produce the specific recombinant protein, GLP1. Samples and lists of standard operating procedures (SOPs) and other important documents, which are necessary to produce the protein commercially using equipments and methods compatible with current good manufacturing practice (CGMP), are also presented.

### References

1. Werner Creutzfeldt, The [pre-] history of the incretin concept, *Regulatory Peptides*, 128, 87-91.
2. Bo Ahren, Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes, *Drug Discovery Today*, 1(2), 207-212.
3. Roeb Garcia-Arrazola, Sun Chau Siu, Gerard Chan, Ian Buchanan, Billy Doyle, Nigel Titchener-Hooker, Frank Baganz, Evaluation of a pH-stat feeding strategy on the production and recovery of Fab' fragments from *E.coli*. *Biochemical Engineering Journal*, 23, 221-230.
4. WHO, A WHO guide to good manufacturing practice requirements - Part 1: Standard operating procedures and master fomulae (1997), Available at: [www.who.int/vaccines-documents/DocsPDF/www9651.pdf](http://www.who.int/vaccines-documents/DocsPDF/www9651.pdf).